Does a restricted energy low glycemic index diet have a different effect on overweight women with or without polycystic ovary syndrome?


Journal

BMC endocrine disorders
ISSN: 1472-6823
Titre abrégé: BMC Endocr Disord
Pays: England
ID NLM: 101088676

Informations de publication

Date de publication:
02 Sep 2019
Historique:
received: 17 07 2019
accepted: 19 08 2019
entrez: 4 9 2019
pubmed: 4 9 2019
medline: 11 2 2020
Statut: epublish

Résumé

Obese women with polycystic ovary syndrome (PCOS) may face additional barriers in achieving weight loss. We aimed to compare the effects of the hypocaloric low glycemic index (LGI) diet on anthropometric variables and insulin resistance in women with and without PCOS and investigate the effect of this diet on the clinical and hormonal features of PCOS women. This interventional study was carried out at the Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Of 108 women invited for the purpose of the present study, 62 participants (PCOS = 28, non-PCOS = 34) followed a 24-week energy restricted LGI diet. Anthropometric, biochemical, hormonal and clinical measurements were documented at baseline, 12 weeks and 24 weeks with intervention. The percentages of weight loss achieved by both the PCOS and non-PCOS groups did not differ significantly (PCOS: -8.04% vs. non-PCOS: -8.09%). No significant difference in decrease of homeostatic model assessment of insulin resistance (HOMA-IR) was observed between the two groups (PCOS = - 0.83 ± 0.33, non PCOS = - 0.79 ± 0.28, P = 0.83). In PCOS women, significant reduction in total testosterone (- 0.91 ± 0.33 nmol/L, P = 0.006), FAI (- 4.47 ± 1.1, P < 0.001) and increase in SHBG (38.98 ± 11.02 nmol/L, P < 0.001) were observed. Menstrual irregularity was improved in 80% of women with PCOS and a significant decrease (32.1%) in occurrence of acne was reported. This diet has equally beneficial effects on anthropometric and metabolic characteristics of overweight women with and without PCOS. This study is registered in the Iranian Randomized Clinical Trials Registry (IRCT, code: IRCT2016092129909N1 ).

Sections du résumé

BACKGROUND BACKGROUND
Obese women with polycystic ovary syndrome (PCOS) may face additional barriers in achieving weight loss. We aimed to compare the effects of the hypocaloric low glycemic index (LGI) diet on anthropometric variables and insulin resistance in women with and without PCOS and investigate the effect of this diet on the clinical and hormonal features of PCOS women.
METHODS METHODS
This interventional study was carried out at the Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Of 108 women invited for the purpose of the present study, 62 participants (PCOS = 28, non-PCOS = 34) followed a 24-week energy restricted LGI diet. Anthropometric, biochemical, hormonal and clinical measurements were documented at baseline, 12 weeks and 24 weeks with intervention.
RESULTS RESULTS
The percentages of weight loss achieved by both the PCOS and non-PCOS groups did not differ significantly (PCOS: -8.04% vs. non-PCOS: -8.09%). No significant difference in decrease of homeostatic model assessment of insulin resistance (HOMA-IR) was observed between the two groups (PCOS = - 0.83 ± 0.33, non PCOS = - 0.79 ± 0.28, P = 0.83). In PCOS women, significant reduction in total testosterone (- 0.91 ± 0.33 nmol/L, P = 0.006), FAI (- 4.47 ± 1.1, P < 0.001) and increase in SHBG (38.98 ± 11.02 nmol/L, P < 0.001) were observed. Menstrual irregularity was improved in 80% of women with PCOS and a significant decrease (32.1%) in occurrence of acne was reported.
CONCLUSIONS CONCLUSIONS
This diet has equally beneficial effects on anthropometric and metabolic characteristics of overweight women with and without PCOS.
TRIAL REGISTRATION BACKGROUND
This study is registered in the Iranian Randomized Clinical Trials Registry (IRCT, code: IRCT2016092129909N1 ).

Identifiants

pubmed: 31477085
doi: 10.1186/s12902-019-0420-1
pii: 10.1186/s12902-019-0420-1
pmc: PMC6720418
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

93

Références

Am J Cardiol. 2001 Apr 1;87(7):827-31
pubmed: 11274935
Am J Clin Nutr. 2002 Jul;76(1):5-56
pubmed: 12081815
J Clin Endocrinol Metab. 2003 Feb;88(2):812-9
pubmed: 12574218
Diabetes. 2003 Mar;52(3):701-7
pubmed: 12606511
Clin Endocrinol (Oxf). 1992 Jun;36(6):537-43
pubmed: 1424179
Fertil Steril. 2004 Jan;81(1):19-25
pubmed: 14711538
J Clin Endocrinol Metab. 2006 Apr;91(4):1357-63
pubmed: 16434451
J Clin Endocrinol Metab. 2007 Feb;92(2):405-13
pubmed: 17090633
Eur J Clin Nutr. 2007 Dec;61 Suppl 1:S122-31
pubmed: 17992183
J Clin Endocrinol Metab. 2008 Sep;93(9):3373-80
pubmed: 18583464
J Hum Nutr Diet. 2008 Aug;21(4):337-45
pubmed: 18721400
Nutr J. 2009 Jan 29;8:5
pubmed: 19178721
J Psychosom Obstet Gynaecol. 2010 Mar;31(1):24-31
pubmed: 20050767
Am J Clin Nutr. 2010 Jul;92(1):83-92
pubmed: 20484445
J Pediatr Adolesc Gynecol. 2011 Jun;24(3):161-5
pubmed: 21419674
J Clin Endocrinol Metab. 2011 Nov;96(11):3533-40
pubmed: 21880803
Acta Derm Venereol. 2012 May;92(3):241-6
pubmed: 22678562
Reprod Biomed Online. 2012 Nov;25(5):500-3
pubmed: 22995747
Endocr Rev. 2012 Dec;33(6):981-1030
pubmed: 23065822
Obes Rev. 2013 Feb;14(2):95-109
pubmed: 23114091
Obesity (Silver Spring). 2013 Aug;21(8):1526-32
pubmed: 23818329
Acta Derm Venereol. 2013 Nov;93(6):644-9
pubmed: 23975508
Nutr Res Pract. 2013 Oct;7(5):385-92
pubmed: 24133618
Reprod Sci. 2014 Feb 11;21(8):1020-1026
pubmed: 24520086
Clin Endocrinol (Oxf). 2015 Sep;83(3):384-8
pubmed: 25660380
Nutr Metab Cardiovasc Dis. 2015 Sep;25(9):795-815
pubmed: 26160327
J Obes Weight Loss Ther. 2015 Apr;5(2):null
pubmed: 26225266
Glob J Health Sci. 2016 Feb 02;8(9):54801
pubmed: 27157182
Neuropsychiatr Dis Treat. 2016 Nov 08;12:2895-2903
pubmed: 27877043
Med Hypotheses. 2016 Nov;96:42-47
pubmed: 27959274
Nutr Metab Cardiovasc Dis. 2017 Nov;27(11):978-984
pubmed: 28958695
Gynecol Endocrinol. 2018 Jul;34(7):589-596
pubmed: 29258367
Acta Diabetol. 2018 Mar;55(3):209-218
pubmed: 29260404
Gynecol Endocrinol. 2018 Dec;34(12):1073-1080
pubmed: 30044162
Hum Reprod Update. 2018 Nov 1;24(6):694-709
pubmed: 30059968
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
Am J Obstet Gynecol. 1981 Aug 1;140(7):815-30
pubmed: 7258262

Auteurs

Farnaz Shishehgar (F)

Department of Midwifery, Faculty of Nursing and Midwifery, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.

Parvin Mirmiran (P)

Nutrition and Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Maryam Rahmati (M)

School of Public Health, Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences, Tehran, Iran.

Maryam Tohidi (M)

Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Fahimeh Ramezani Tehrani (F)

Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, No 24, Parvane Street, Yaman Street, Velenjak, Tehran, Iran. ramezani@endocrine.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH